Send us Feedback

Bioheart (BHRT)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Bioheart Announces New Brand Image, Launches Redesigned Website and New Company Logo
Globe Newswire  Jun 26  Comment 
SUNRISE, Fla., June 26, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced today that the company has launched a new brand image and redesigned website including a new company logo and tagline aimed at increasing brand awareness and
Bioheart's Chief Science Officer Kristin Comella Presents at 10th Annual Meeting of International Society for Stem Cell Research in Yokohama, Japan June 13-16, 2012
Globe Newswire  Jun 25  Comment 
SUNRISE, Fla., June 25, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced today that Kristin Comella, the company's Chief Science Officer presented at the 10th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in
Bioheart and Ageless Regenerative Partner to Advance Stem Cell Field With New Laboratory Training Program on June 23-24, 2012
Globe Newswire  May 29  Comment 
SUNRISE, Fla., May 29, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) announced today that it will offer another laboratory training course in partnership with the Ageless Regenerative Institute, an organization dedicated to the standardization
Bioheart's President/CEO Mike Tomas Inducted Into Miami Dade College Hall of Fame
Globe Newswire  May 3  Comment 
SUNRISE, Fla., May 3, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced today that Mike Tomas, the company's President/CEO, has been named a 2012 Hall of Famer by Miami Dade College (MDC). Tomas is one of 25 alumni presented with its top
Bioheart Inc. Wins 2012 Technology Leaders of The Year Award
Globe Newswire  May 1  Comment 
SUNRISE, Fla., May 1, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced today that it has received the 2012 Greater Miami Chamber of Commerce Technology Leaders of the Year award, in the Bioscience company category. The company was
Bioheart Named 2012 Finalist in Technology Leaders of the Year Awards
Globe Newswire  Apr 11  Comment 
SUNRISE, Fla., April 11, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) announced today that it has been named a 2012 finalist in the Bioscience company category for the Greater Miami Chamber of Commerce Technology Leaders of the Year award
Bioheart and Ageless Partner to Advance Stem Cell Field With Laboratory Training Programs
Globe Newswire  Mar 15  Comment 
SUNRISE, Fla., March 15, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced today that it has successfully conducted a laboratory training course in partnership with the Ageless Regenerative Institute, an organization dedicated to the
Bioheart Consortium of Directors and Shareholders Purchase Note Showing Continued Confidence in Company's Future
Globe Newswire  Mar 14  Comment 
SUNRISE, Fla., March 14, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) announced today that NorthStar Biotech LLC, a consortium of Bioheart Directors and Shareholders, has purchased a company note in the amount of $572,000 previously held by
Bioheart Appoints Advisory Board of Business and Financial Executives
Globe Newswire  Feb 29  Comment 
SUNRISE, Fla., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT) announced today it has appointed a five-member Advisory Board comprised of local and international business, financial and marketing executives to assist in the development
Bioheart Announces University of Miami as Clinical Site for ANGEL Trial of LipiCell(TM)
Globe Newswire  Feb 28  Comment 
SUNRISE, Fla., Feb. 28, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced that the company will conduct the ANGEL trial using adipose (fat) derived stem cell technology or LipiCell™ at the University of Miami Miller School of Medicine.




more ▼WIKI ANALYSIS
 
TOP CONTRIBUTORS
Sr. Director
Michael Sweeney
ProActive Ne...

Bioheart (OTC: BHRT; Twitter: $BHRT) seeks to be the "go to technology partner for heart failure specialists and their patients".

The company's flagship product MyoCell is an adult muscle stem cell composition, also known as immature myoblasts, derived and processed from patient's own thigh muscle. These cells are delivered to a patient's heart via the MyoCath needle tipped catheter or a similar device which is inserted through the patient's groin and is directed to the inside myocellof the heart where the injections are made.

MyoCell has been in clinical trials for treating advanced heart failure patients since early 2001. A 2nd generation composition MyoCell SDF-1 received FDA approval for clinical trials. This composition is made up of genetically modified cells that over express the stromal derived factor 1 protein that has been shown to improve blood vessel formation and muscle development.

Bioheart. has also initiated clinical evaluation of methods of treating heart ischemia, acute myocardial infarctions and lower limb ischemia utilizing adipose (fat) derived cells. Bioheart is focused on heart failure and has a building pipeline of product developments to assist care providers in treating and caring for these patients.

Retrieved from "http://www.wikinvest.com/stock/Bioheart_(BHRT)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki